These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 31054942)
1. Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells. Lorenzetti R; Janowska I; Smulski CR; Frede N; Henneberger N; Walter L; Schleyer MT; Hüppe JM; Staniek J; Salzer U; Venhoff A; Troilo A; Voll RE; Venhoff N; Thiel J; Rizzi M J Autoimmun; 2019 Jul; 101():145-152. PubMed ID: 31054942 [TBL] [Abstract][Full Text] [Related]
2. Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells. Liu PC; Ssu CT; Tsao YP; Liou TL; Tsai CY; Chou CT; Chen MH; Leu CM Arthritis Res Ther; 2020 Mar; 22(1):64. PubMed ID: 32228715 [TBL] [Abstract][Full Text] [Related]
3. Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis. Bonelli M; Göschl L; Blüml S; Karonitsch T; Hirahara K; Ferner E; Steiner CW; Steiner G; Smolen JS; Scheinecker C Rheumatology (Oxford); 2016 Apr; 55(4):710-20. PubMed ID: 26672908 [TBL] [Abstract][Full Text] [Related]
4. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960 [TBL] [Abstract][Full Text] [Related]
5. Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn. Bernett MJ; Chu SY; Leung I; Moore GL; Lee SH; Pong E; Chen H; Phung S; Muchhal US; Horton HM; Lazar GA; Desjarlais JR; Szymkowski DE MAbs; 2013; 5(3):384-96. PubMed ID: 23549103 [TBL] [Abstract][Full Text] [Related]
6. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. Scarsi M; Paolini L; Ricotta D; Pedrini A; Piantoni S; Caimi L; Tincani A; Airò P J Rheumatol; 2014 Apr; 41(4):666-72. PubMed ID: 24584924 [TBL] [Abstract][Full Text] [Related]
7. Tumour necrosis factor α augments the inhibitory effects of CTLA-4-Ig on osteoclast generation from human monocytes via induction of CD80 expression. Oi K; Tokunaga T; Kuranobu T; Yukawa K; Kohno H; Yoshida Y; Mokuda S; Hirata S; Sugiyama E Clin Exp Immunol; 2019 Jun; 196(3):392-402. PubMed ID: 30724348 [TBL] [Abstract][Full Text] [Related]
8. Memory B Cells and Response to Abatacept in Rheumatoid Arthritis. Gazeau P; Alegria GC; Devauchelle-Pensec V; Jamin C; Lemerle J; Bendaoud B; Brooks WH; Saraux A; Cornec D; Renaudineau Y Clin Rev Allergy Immunol; 2017 Oct; 53(2):166-176. PubMed ID: 28477078 [TBL] [Abstract][Full Text] [Related]
9. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886 [TBL] [Abstract][Full Text] [Related]
10. B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes. Linsley PS; Greenbaum CJ; Speake C; Long SA; Dufort MJ JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830871 [TBL] [Abstract][Full Text] [Related]
11. CD80 expression is induced on activated B cells following stimulation by CD86. Sahoo NC; Rao KV; Natarajan K Scand J Immunol; 2002 Jun; 55(6):577-84. PubMed ID: 12028560 [TBL] [Abstract][Full Text] [Related]
12. In Vivo Imaging of Local Inflammation: Monitoring LPS-Induced CD80/CD86 Upregulation by PET. Taddio MF; Castro Jaramillo CA; Runge P; Blanc A; Keller C; Talip Z; Béhé M; van der Meulen NP; Halin C; Schibli R; Krämer SD Mol Imaging Biol; 2021 Apr; 23(2):196-207. PubMed ID: 32989622 [TBL] [Abstract][Full Text] [Related]
14. CD80 on Human T Cells Is Associated With FoxP3 Expression and Supports Treg Homeostasis. Soskic B; Jeffery LE; Kennedy A; Gardner DH; Hou TZ; Halliday N; Williams C; Janman D; Rowshanravan B; Hirschfield GM; Sansom DM Front Immunol; 2020; 11():577655. PubMed ID: 33488578 [TBL] [Abstract][Full Text] [Related]
15. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation. Vandenborre K; Van Gool SW; Kasran A; Ceuppens JL; Boogaerts MA; Vandenberghe P Immunology; 1999 Nov; 98(3):413-21. PubMed ID: 10583602 [TBL] [Abstract][Full Text] [Related]
16. Abatacept does not induce direct gene expression changes in antigen-presenting cells. Carman JA; Davis PM; Yang WP; Zhu J; Chang H; He A; Truong A; Suchard SJ; Nadler SG J Clin Immunol; 2009 Jul; 29(4):479-89. PubMed ID: 19259798 [TBL] [Abstract][Full Text] [Related]
17. CD80 and CD86 differentially regulate mechanical interactions of T-cells with antigen-presenting dendritic cells and B-cells. Lim TS; Goh JK; Mortellaro A; Lim CT; Hämmerling GJ; Ricciardi-Castagnoli P PLoS One; 2012; 7(9):e45185. PubMed ID: 23024807 [TBL] [Abstract][Full Text] [Related]
18. CTLA-4 blockade in the treatment of rheumatoid arthritis: an update. Cutolo M; Sulli A; Paolino S; Pizzorni C Expert Rev Clin Immunol; 2016; 12(4):417-25. PubMed ID: 26679631 [TBL] [Abstract][Full Text] [Related]
19. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Linsley PS; Greene JL; Brady W; Bajorath J; Ledbetter JA; Peach R Immunity; 1994 Dec; 1(9):793-801. PubMed ID: 7534620 [TBL] [Abstract][Full Text] [Related]
20. Intracellular concentrations of Ca(2+) modulate the strength of signal and alter the outcomes of cytotoxic T-lymphocyte antigen-4 (CD152)-CD80/CD86 interactions in CD4(+) T lymphocytes. Ahmed A; Mukherjee S; Nandi D Immunology; 2009 Mar; 126(3):363-77. PubMed ID: 18710402 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]